Related Experiment Video
Updated: Jun 26, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy
Mark G Frattini1, Peter G Maslak
1Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Abstract:
Acute myeloid leukemia is a heterogeneous disease. Standard treatments may be applied to biologically distinct subgroups, resulting in different treatment outcomes. The concept of risk-adapted therapy allows for recognition of this biologic diversity by incorporating key biologic features, such as cytogenetic and molecular markers, when formulating treatment regimens and investigating emerging targeted therapies based on disease characteristics.

